Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours
Introduction: Neuroendocrine tumours (NETs) arising from the rectum are more common in the Asian population. Current treatment options include somatostatin analogues, chemotherapy, and more recently, peptide-receptor radionuclide therapy (PRRT). Peptide receptor radionuclide therapy (PRRT) has been shown to be effective in the treatment of advanced gastroenteropancreatic (GEP) tumours with minimal adverse effects. Studies have also suggested that rectal NETs show good response to PRRT, better than GEP NETs.
Aim(s): We aimed to review the response of patients with advanced rectal NETs compared to NETs from other primary sites following PRRT.
Materials and methods: A retrospective review was done on patients with NETs who had undergone PRRT from 2012 till March 2019. Statistical analysis comparing the difference in time to progression and overall survival was done for patients with rectal NETs compared to those with NETs from other primary sites.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.